UK myeloma forum (UKMF) and nordic myeloma study group (NMSG): Guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS)

British Journal of Haematology

Volumn 147, Issue 1, 2009, Pages 22-42

  Bird, Jenny ^a,m   Behrens, Judith ^b   Westin, Jan ^c   Turesson, Ingemar ^d   Drayson, Mark ^e   Beetham, Robert ^f   D'Sa, Shirley ^g   Soutar, Richard ^h   Waage, Anders ⁱ   Gulbrandsen, Nina ^j   Gregersen, Henrik ^k   Low, Eric ^l  

^a BRISTOL HAEMATOLOGY AND ONCOLOGY CENTRE   (United Kingdom)

^b ST HELIER HOSPITAL   (United Kingdom)

^c SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

^d LUND UNIVERSITY HOSPITAL   (Sweden)

^e UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^f FRENCHAY HOSPITAL   (United Kingdom)

^g UNIVERSITY COLLEGE LONDON   (United Kingdom)

^h WESTERN INFIRMARY   (United Kingdom)

ⁱ TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^j ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^k AALBORG UNIVERSITY HOSPITAL   (Denmark)

^l AARHUS UNIVERSITY HOSPITAL   (Denmark)

^m British Society for Haematology   (United Kingdom)

more..

Author keywords

Amyloidosis; Immunoglobulin; Laboratory haematology; Lymphoid malignancies; Myeloma

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; LENALIDOMIDE; M PROTEIN; THALIDOMIDE;

AGE DISTRIBUTION; AMYLOIDOSIS; B LYMPHOCYTE; BONE MARROW BIOPSY; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CYTOGENETICS; DENDRITIC CELL; DIFFERENTIAL DIAGNOSIS; DISEASE COURSE; ERYTHROCYTE SEDIMENTATION RATE; FOLLOW UP; HEALTH CARE PERSONNEL; HEALTH SURVEY; HOSPITAL PATIENT; HUMAN; IMMUNOGLOBULIN BLOOD LEVEL; LIGHT CHAIN; MALIGNANT TRANSFORMATION; MASS SCREENING; MONOCLONAL IMMUNOGLOBULINEMIA; MULTIPLE MYELOMA; NONHODGKIN LYMPHOMA; OSTEOPENIA; PATIENT MONITORING; PLASMA VISCOSITY; PLASMACYTOMA; POLYNEUROPATHY; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN ELECTROPHORESIS; RACE DIFFERENCE; REVIEW; RISK FACTOR; WALDENSTROEM MACROGLOBULINEMIA;

EID: 70349195919     PISSN: 00071048     EISSN: 13652141     Source Type: Journal    
DOI: 10.1111/j.1365-2141.2009.07807.x     Document Type: Review

References (70)

1. Alexanian, R. (1975) Monoclonal gammopathy in lymphoma. Archives of Internal Medicine, 135, 62 66.
2. Amara, S., Dezube, B.J., Cooley, T.P., Pantanowitz, L. Aboulafia, D.M. (2006) HIV-associated monoclonal gammopathy: a retrospective analysis of 25 patients. Clinical Infectious Diseases, 43, 1198 1205.
3. Avet-Loiseau, H., Facon, T., Daviet, A., Godon, C., Rapp, M.J., Harousseau, J.L., Grosbois, B. Bataille, R. & Intergroupe Francophone du Myélome (1999) 14q32 translocations and monosomy 13 observed in monoclonal gammopathy of undetermined significance delineate a multistep process for the oncogenesis of multiple myeloma. Cancer Research, 59, 4546 4550.
4. Axelsson, U., Bachmann, R. Hällén, J. (1966) Frequency of pathological proteins (M-components) in 6,995 sera from an adult population. Acta Medica Scandinavica, 179, 235 247.
5. Azar, H.A., Hill, W.T. Osserman, E.F. (1957) Malignant lymphoma and lymphatic leukemia associated with myeloma-type serum proteins. The American Journal of Medicine, 23, 239 249.
6. Baldini, L., Guffanti, A., Cesana, B.M., Colombi, M., Chiorboli, O., Damilano, I. Maiolo, A.T. (1996) Role of different hematologic variables in defining the risk of malignant transformation in monoclonal gammopathy. Blood, 87, 912 918.
7. Berenson, J.R., Yellin, O., Boccia, R.V., Flam, M., Wong, S.F., Batuman, O., Moezi, M.M., Woytowitz, D., Duvivier, H., Nassir, Y. Swift, R.A. (2008) Zoledronic acid markedly improves bone mineral density for patients with monoclonal gammopathy of undetermined significance and bone loss. Clinical Cancer Research, 14, 6289 6295.
8. Bird, J., Cavenagh, J., Hawkins, P., Lachmann, H., Mehta, A. Samson, D. on behalf of the UK Myeloma Forum (2004) Guidelines on the diagnosis and management of AL amyloidosis. British Journal of Haematology, 125, 681 700.
9. Blade, J., Lopez-Guillermo, A., Rozman, C., Cervantes, F., Salgado, C., Aguilar, J.L., Vives-Corrons, J.L. Montserrat, E. (1992) Malignant transformation and life expectancy in monoclonal gammopathy of undetermined significance. British Journal of Haematology, 81, 391 394.
10. Bradwell, A.R., Carr-Smith, H.D., Mead, G.P., Harvey, T.C. Drayson, M.T. (2003) Serum test for assessment of patients with Bence Jones Myeloma. Lancet, 361, 489 491.
11. Caforio, A.L., Gambino, A., Belloni Fortina, A., Piaserico, S., Scarpa, E., Feltrin, G., Tona, F., Pompei, E., Tonin, E., Amadori, G., Thiene, G., Dalla Volta, S., Peserico, A. Casarotto, D. (2001) Monoclonal gammopathy in heart transplantation: risk factor analysis and relevance of immunosuppressive load. Transplantation Proceedings, 33, 1583 1584.
12. Cesana, C., Klersy, C., Barbarano, L., Nosari, A.M., Crugnola, M., Pungolino, E., Gargantini, L., Granata, S., Valentini, M. Morra, E. (2002) Prognostic factors for malignant transformation in monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Journal of Clinical Oncology, 20, 1625 1634.
13. Cohen, H.J., Crawford, J., Rao, M.K., Pieper, C.F. Currie, M.S. (1998) Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. American Journal of Medicine, 104, 439 444.
14. Crawford, J., Eye, M.K. Cohen, H.J. (1987) Evaluation of monoclonal gammopathies in the 'well' elderly. American Journal of Medicine, 82, 39 45.
15. D'Sa, S., Abildgaard, N., Tighe, J., Shaw, P. Hall-Craggs, M. (2007) Guidelines for the use of imaging in the management of myeloma. British Journal of Haematology, 137, 49 63.
16. Daoud, M.S., Lust, J.A., Kyle, R.A. Pittelkow, M.R. (1999) Monoclonal gammopathies and associated skin disorders. Journal of the American Academy of Dermatology, 40, 507 535.
17. Dispenzieri, A. Kyle, R.A. (2005) Neurological aspects of multiple myeloma and related disorders. Best Practice and Research. Clinical Haematology, 18, 673 688.
18. Dizdar, O., Erman, M., Cankurtaran, M., Halil, M., Ulger, Z., Yavuz, B.B., Ariogul, S., Pinar, A., Harputluoglu, H., Kars, A. Celik, I. (2008) Lower bone mineral density in geriatric patients with monoclonal gammopathy of undetermined significance. Annals of Hematology, 87, 57 60.
19. Drayson, M., Begum, G., Basu, S., Makkuni, S., Dunn, J., Barth, N. Child, J.A. (2006) Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood, 108, 2013 2019.
20. Fine, J.M., Lambin, P. Leroux, P. (1972) Frequency of monoclonal gammopathy ('M-components') in 13 400 sera from blood donors. Vox Sanguinis, 23, 336 343.
21. Fonseca, R. Hayman, S. (2007) Waldenström macroglobulinaemia. British Journal of Haematology, 138, 700 720.
22. Fonseca, R., Bailey, R.J., Ahmann, G.J., Rajkumar, S.V., Hoyer, J.D., Lust, J.A., Kyle, R.A., Gertz, M.A., Greipp, P.R. Dewald, G.W. (2002) Genomic abnormalities in monoclonal gammopathy of uncertain significance. Blood, 100, 1417 1424.
23. Giraldo, M.P., Rubio-Félix, D., Perella, M., García, J.A., Bergua, J.M. Giralt, M. (1991) Gammapatías monoclonales de significado indeterminado. Aspectos clínicos, biológicos y evolutivos de 397 casos. Sangre (Barc), 36, 377 382.
24. Gregersen, H., Mellemkjær, L., Ibsen, J.S., Dahlerup, J.F., Thomassen, L. Sørensen, H.T. (2001a) The impact of M-component type and immunoglobulin concentration on the risk of malignant transformation in patients with monoclonal gammopathy of undetermined significance. Haematologica, 86, 1172 1179.
25. Gregersen, H., Ibsen, J.S., Mellemkjær, L., Dahlerup, J.F., Olsen, J.H. Sørensen, H.T. (2001b) Mortality and causes of death in patients with monoclonal gammopathy of undetermined significance. British Journal of Haematology, 112, 353 357.
26. Gregersen, H., Jensen, P., Gislum, M., Jørgensen, B., Sørensen, H.T. Nørgaard, M. (2006) Fracture risk in patients with monoclonal gammopathy of undetermined significance. British Journal of Haematology, 135, 62 67.
27. Hadden, R.D., Nobile-Orazio, E., Sommer, C., Hahn, A., Illa, I., Morra, E., Pollard, J., Hughes, R.A., Bouche, P., Cornblath, D., Evers, E., Koski, C.L., Léger, J.M., Van den Bergh, P., van Doorn, P. van Schaik, I.N. (2006) European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of paraproteinaemic demyelinating neuropathies: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. European Journal of Neurology, 13, 809 818. (Pubitemid 44124676)
28. Hardiman, K.L., Horn, S., Manoharan, A., Phadke, K., Gibson, J., McGuigan, L. Sturgess, A. (1994) Rheumatic autoantibodies in the sera of patients with paraproteins. Clinical and Experimental Rheumatology, 12, 363 368.
29. Hughes, R.A., Bouche, P., Cornblath, D.R., Evers, E., Hadden, R.D., Hahn, A., Illa, I., Koski, C.L., Leger, J.M., Nobile-Orazio, E., Pollard, J., Sommer, C., Van den Bergh, P., van Doorn, P.A. van Schaik, I.N. (2006) European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society. European Journal of Neurology, 13, 326 332.
30. Idilman, R., Colantoni, A., De Maria, N., Alkan, S., Nand, S. Van Thiel, D.H. (2004) Lymphoproliferative disorders in chronic hepatitis C. Journal of Viral Hepatitis, 11, 302 309.
31. International Myeloma Working Group (2003) Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. British Journal of Haematology, 121, 749 757.
32. Kumar, S., Rajkumar, S.V., Kyle, R.A., Lacy, M.Q., Dispenzieri, A., Fonseca, R., Lust, J.A., Gertz, M.A., Greipp, P.R. Witzig, T.E. (2005) Prognostic value of circulating plasma cells in monoclonal gammopathy of undetermined significance. Journal of Clinical Oncology, 23, 5668 5674.
33. Kyle, R.A. (1978) Monoclonal gammopathy of uncertain significance; natural history in 241 cases. Mayo Clinic Proceedings, 50, 29 40.
34. Kyle, R.A. Gahrton, J.P. (1987) The spectrum of IgM monoclonal gammopathy in 430 cases. Mayo Clinic Proceedings, 62, 719 731.
35. Kyle, R.A. Rajkumar, S.V. (2006) Monoclonal gammopathy of undetermined significance. British Journal of Haematology, 134, 573 589.
36. Kyle, R.A., Bayrd, E.D., McKenzie, B.F. Heck, F.J. (1960) Diagnostic criteria for electrophoretic patterns of serum and urinary proteins in multiple myeloma. Study of one hundred and sixty-five multiple myeloma patients and of seventy-seven non myeloma patients with similar electrophoretic patterns. Journal of the American Medical Association, 174, 245 251.
37. Kyle, R.A., Therneau, T.M., Rajkumar, S.V., Offord, J.R., Larson, D.R., Plevak, M.F. Melton, III., L.J. (2002) A long- term study of prognosis in monoclonal gammopathy of undetermined significance. New England Journal of Medicine, 346, 564 569.
38. Kyle, R.A., Gertz, M.A., Witzig, T.E., Lust, J.A., Lacy, M.Q., Dispenzieri, A., Fonseca, R., Rajkumar, S.V., Offord, J.R., Larson, D.R., Plevak, M.E., Therneau, T.M. Greipp, P.R. (2003) Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clinic Proceedings, 78, 21 33.
39. Kyle, R.A., Therneau, T.M., Rajkumar, S.V., Larson, D.R., Plevak, M.F. Melton, III., L.J. (2004) Long-term follow-up of 241 patients with monoclonal gammopathy of undetermined significance: the original Mayo Clinic series 25 years later. Mayo Clinic Proceedings, 79, 859 866.
40. Kyle, R.A., Therneau, T.M., Rajkumar, S.V., Larson, D.R., Plevak, M.F., Offord, J.R., Dispenzieri, A., Katzmann, J.A. Melton, J. (2006) Prevalence of monoclonal gammopathy of undetermined significance. New England Journal of Medicine, 354, 1362 1369.
41. Lin, P., Hao, S., Handy, B.C., Bueso-Ramos, C.E. Medeiros, L.J. (2005) Lymphoid neoplasms associated with IgM paraprotein: a study of 382 patients. American Journal of Clinical Pathology, 123, 200 205.
42. Malacrida, V., De Francesco, D., Banfi, G., Porta, F.A. Riches, P.G. (1987) Laboratory investigation of monoclonal gammopathy during 10 years of screening in a general hospital. Journal of Clinical Pathology, 40, 793 797.
43. Malik, A.A., Ganti, A.K., Potti, A., Levitt, R. Hanley, J.F. (2002) Role of Helicobacter pylori infection in the incidence and clinical course of monoclonal gammopathy of undetermined significance. The American Journal of Gastroenterology, 97, 1371 1374.
44. Melton, L.J., Rajkumar, S.V., Khosla, S., Achenbach, S.J., Oberg, A.L. Kyle, R.A. (2004) Fracture risk in monoclonal gammopathy of undetermined significance. Journal of Bone and Mineral Research, 19, 25 30.
45. Merlini, G. Stone, M.J. (2006) Dangerous small B-cell clones. Blood, 108, 2520 2530.
46. Musto, P., Petrucci, M.T., Bringhen, S., Guglielmelli, T., Caravita, T., Bongarzoni, V., Andriani, A., D'Arena, G., Balleari, E., Pietrantuono, G., Boccadoro, M., Palumbo, A. GIMEMA (Italian Group for Adult Hematologic Diseases)/Multiple Myeloma Working Party and the Italian Myeloma Network (2008) A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma. Cancer, 113, 2835.
47. Nobile-Orazio, E., Barbieri, S., Baldini, L., Marmiroli, P., Carpo, M., Premoselli, S., Manfredini, E. Scarlato, G. (1992) Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies. Acta neurologica Scandinavica, 85, 383 390.
48. Owen, R.G., Treon, S.P., AL-Katib, A., Fonseca, R., Greipp, P.R., McMaster, M.L., Morra, E., Pangalis, G.A., San Miguel, J.F., Branagan, A.R. Dimopoulos, M.A. (2003) Clinicopathological definition of Waldenstrom′s Macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom′s Macroglobulinemia. Seminars in Oncology, 30, 110 115.
49. Pasqualetti, P., Festuccia, V., Collacciani, A. Casale, R. (1997) The natural history of monoclonal gammopathy of undetermined significance. A 5- to 20-year follow-up of 263 cases. Acta Haematologica, 97, 174 179.
50. Pepe, J., Petrucci, M.T., Nofroni, I., Fassino, V., Diacinti, D., Romagnoli, E. Minisola, S. (2006) Lumbar bone mineral density as the major factor determining increased prevalence of vertebral fractures in monoclonal gammopathy of uncertain significance. British Journal of Haematology, 134, 485 490.
51. Pepe, J., Petrucci, M.T., Mascia, M.L., Piemonte, S., Fassino, V., Romagnoli, E. Minisola, S. (2008) The effects of alendronate treatment in osteoporotic patients affected by monoclonal gammopathy of undetermined significance. Calcified Tissue International, 82, 418 426.
52. Pérez-Persona, E., Vidriales, M.B., Mateo, G., García-Sanz, R., Mateos, M.V., de Coca, A.G., Galende, J., Martín-Nuñez, G., Alonso, J.M., de Las Heras, N., Hernández, J.M., Martín, A., López-Berges, C., Orfao, A. San Miguel, J.F. (2007) New criteria to identify risk of progression in monoclonal gammopathy of uncertain significance and smoldering multiple myeloma based on multiparameter flow cytometry analysis of bone marrow plasma cells. Blood, 110, 2586 2592.
53. Radl, J., Valentijn, R.M., Haaijman, J.J. Paul, L.C. (1985) Monoclonal gammopathies in patients undergoing immunosuppressive treatment after renal transplantation. Clinical Immunology and Immunopathology, 37, 98 102.
54. Rajkumar, S.V., Mesa, A.M., Fonseca, R., Schroeder, G., Plevak, M.F., Dispenzieri, A., Lacy, M.Q., Lust, J.A., Witzig, T.E., Gertz, M.A., Kyle, R.A., Russell, S.J. Greipp, P.R. (2002) Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance multiple myeloma and primary amyloidosis. Clinical Cancer Research, 8, 2210 2216.
55. Rajkumar, S.V., Kyle, R.A., Therneau, T.M., Melton, III., L.J., Bradwell, A.R., Clark, R.J., Larson, D.R., Plevak, M.F., Dispenzieri, A. Katzmann, J.A. (2005) Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood, 106, 812 817.
56. Rajkumar, S.V., Lacy, M.Q. Kyle, R.A. (2007) Monoclonal gammopathy of undetermined significance and smoldering multiple myeloma. Blood Reviews, 21, 255 265.
57. Rawstron, A.C., Jones, R.A., Ferguson, C., Hughes, G., Selby, P., Reid, C., Dalal, S., Howard, M., Smith, G., Hillmen, P., Owen, R.G. Jack, A.S. (2007) Outreach monitoring service for patients with indolent B-cell and plasma cell disorders: a UK experience. British Journal of Haematology, 139, 845 848.
58. Renoult, E., Bertrand, F. Kessler, M. (1988) Monoclonal gammopathies in HBsAg-positive patients with renal transplants. New England Journal of Medicine, 318, 1205.
59. Rosiñol, L., Cibeira, M.T., Montoto, S., Rozman, M., Esteve, J., Filella, X. Bladé, J. (2007) Monoclonal gammopathy of undetermined significance: predictors of malignant transformation and recognition of an evolving type characterized by a progressive increase in M protein size. Mayo Clinic Proceedings, 82, 428 834.
60. Saleun, J.P., Vicariot, M., Deroff, P. Morin, J.F. (1982) Monoclonal gammopathies in the adult population of Finistère, France. Journal of Clinical Pathology, 35, 63 68.
61. Sallah, S., Husain, A., Wan, J., Vos, P. Nguyen, N. (2004) The risk of venous thromboembolic disease in patients with monoclonal gammopathy of undetermined significance. Annals of Oncology, 15, 1490 1494.
62. Smith, A., Wisloff, F. Samson, D. on behalf of the UK Myeloma Forum and Nordic Myeloma Study Group (2006) Guidelines on the diagnosis and management of multiple myeloma 2005. British Journal of Haematology, 132, 410 451.
63. Soutar, R., Lucraft, H., Jackson, G., Reece, A., Bird, J., Low, E. Samson, D. on behalf of the UK Myeloma Forum (2004) Guidelines on the diagnosis and management of solitary plasmacytoma of bone and solitary extramedullary plasmacytoma. British Journal of Haematology, 124, 717 726. (Pubitemid 38365776)
64. Srkalovic, G., Cameron, M., Rybicki, L., Deitcher, S., Kattke-Marchant, K. Hussein, M. (2004) Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease. Cancer, 101, 558 566.
65. Van De Donk, N., De Weerdt, O., Eurelings, M., Bloem, A. Lokhorst, H. (2001) Malignant transformation of monoclonal gammopathy of undetermined significance: cumulative incidence and prognostic factors. Leukemia and Lymphoma, 42, 609 618.
66. Van de Poel, M.H., Coebergh, J.W. Hillen, H.F. (1995) Malignant transformation of monoclonal gammopathy of undetermined significance among out-patients of a community hospital in Southeastern Netherlands. British Journal of Haematology, 91, 121 125.
67. Vladutiu, A.O. (1987) Prevalence of M-proteins in serum of hospitalised patients: physicians' response to finding M-proteins in serum protein electrophoresis. Annals of Clinical Laboratory Sciences, 17, 157 161.
68. Yi, Q., Desikan, R., Barlogie, B. Munshi, N. (2002) Optimizing dendritic cell based immunotherapy in multiple myeloma. British Journal of Haematology, 117, 297 305.
69. Yin, C.C., Lin, P., Carney, D.A., Handy, B.C., Rassidakis, G.Z., Admirand, J.H., Keating, M.J. Medeiros, L.J. (2005) Chronic lymphocytic leukemia/small lymphocytic lymphoma associated with IgM paraprotein. American Journal of Clinical Pathology, 123, 594 602.
70. Zent, C.S., Wilson, C.S., Tricot, G., Jagannath, S., Siegel, D., Desikan, K.R., Munshi, N., Bracy, D., Barlogie, B. Butch, A.W. (1998) Oligoclonal protein bands and Ig isotype switching in multiple myeloma treated with high-dose therapy and hematopoietic cell transplantation. Blood, 91, 3518 3523. (Pubitemid 28193907)